New hope for rare lymphoma: targeted drug shows promise in small trial
NCT ID NCT05442554
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed Phase 4 trial tested the drug brentuximab vedotin in 10 Chinese adults with a rare type of skin lymphoma called CD30-positive cutaneous T-cell lymphoma. The goal was to see if the drug could shrink or eliminate cancer for at least 4 months and to check for long-term side effects. Participants received the drug through a vein every 3 weeks for up to 16 cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- brentuximab vedotin (a drug given through a vein)
- What this could lead to
- If it works, this could offer a treatment option for Chinese patients with this rare lymphoma that targets cancer cells directly.
- What could go wrong
- This is a small, completed Phase 4 study with only 10 participants, so results may not apply broadly. Side effects from the drug are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200040, China
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
-
Peking University Third Hospital
Beijing, Beijing Municipality, 100191, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.